Open AccessDirect healthcare cost comparison of Fluticasone propionate/Salmeterol vs Budesonide/Formoterol Maintenance And Reliever Therapy for moderate/severe asthma: Results from Thailand
Author(s) -
Torsak Bunupuradah,
Watchara Boonsawat,
Jatupum Kamrapit,
Bhumika Aggarwal
Publication year - 2021
Publication title -
asian pacific journal of allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.405
H-Index - 33
ISSN - 0125-877X
DOI - 10.12932/ap-180421-1117
Subject(s) - salmeterol , formoterol , medicine , budesonide , fluticasone propionate , asthma , fluticasone , health care , pediatrics , emergency medicine , economics , economic growth
Inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) for moderate/severe asthma i.e. regular Fluticasone propionate/Salmeterol (FP/Salm) with as-needed short acting beta-2 agonist (SABA) or ICS/Formoterol Maintenance And Reliever Therapy (MART) are the recommended options.